

Temporal trends on percutaneous mitral commissurotomy: 30 years of experience.

Cyrielle Desnos, Bernard Iung, Dominique Himbert, Grégory Ducrocq, Marina Urena, Bertrand Cormier, Eric Brochet, Phalla Ou, Alec Vahanian, Claire Bouleti.

Bichat Hospital, Paris, France

29 C JOURNÉES E UROPÉENNES de la SOCIÉTÉ F RANÇAISE de CARDIOLOGIE 29 C E UROPEAN D'AYS of the F RENCH SOCIETY of CARDIOLOGY



Disclosure Statement of Financial Interest

I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company or I receive compensation or fees or research grants with a commercial company :

Speaker's name : Cyrielle Desnos, Paris


✓ I do not have any potential conflict of interest


29-S JOURNÉES E UROPÉENNES de la SOCIÉTÉ F RANÇAISE de CARDIOLOGIE 29th E UROPEAN DAYS of the F RENCH SOCIETY of CARDIOLOGY





Introduction

- Percutaneous mitral commissurotomy (PMC) = among 1st available percutaneous technique for the treatment of valvular diseases
- Described by Inoue in 1984










Inoue K et al. J Thorac Cardiovasc Surg. 1984; 87:394-402



OBJECTIVES



- Reference treatment for mitral stenosis (MS)
- Change in patients' profile overtime



Time

 \rightarrow analyze the changes of patients' characteristics over 30 years \rightarrow determine the predictive factors of poor immediate results (PIR) of PMC

Soler-Soler J, Galve E. Heart 2000;83:721-5





• Patients

From 1986 to 2016, analyse of years 1987, 1996, 2006, 2016


Monocentric : Bichat hospital, Paris, France,

All patients undergoing PMC

Valve anatomy assessment

Calcification grade

Cormier score



- **Group 1** : Pliable valves, mild impairment of subvalvular apparatus (chordae ≥10 mm)
- **Group 2** : Pliable valves, severe disease of subvalvular apparatus (chordae <10 mm)

Group 3 : Valve calcification confirmed by fluoroscopy



Methods : Good immediate results of PMC

Composite endpoint:


Final mitral value area (MVA) $\ge 1.5 \text{ cm}^2$ AND

Mitral regurgitation (MR) \leq grade 2



Results: clinical characteristics

Variables	1987	1996	2006	2016	Р
	n= 111	n= 202	n= 205	n= 85	
Male gender, n (%)	27 (24)	39 (19)	39 (19)	23 (27)	0.33
NYHA class 3-4	92 (83)	128 (63)	120 (59)	44 (54)	<0.0001
History of PMC	0	11 (5)	32 (16)	10 (12)	<0.0001






Variables	1987	1996	2006	2016	Р
	n= 111	n= 202	n= 205	n= 85	
MVA (cm ²)	$1,04 \pm 0,23$	1,03±0,22	$1,03 \pm 0,24$	1,07± 0,26	0,42
Mitral gradient (mmHg)	10,8±5,4	$10,2\pm 4,1$	9,5±4,5	$10,1\pm 4,7$	0,13
MR grade 2	6 (5)	18 (9)	21 (10)	10 (12)	0,05
Systolic PAP (mmHg)	31,9±12	46,1±13	43,9±13	46,8±16	<0.0001



Société

Française Cardiologie

de




Less favourable over years: presence and extent of calcification





1.7% complication rate overall (hemopericardium, death, stroke, MR >2)





3 factors identified in multivariate analysis:


Variables	GIR n= 519	Poor results n= 84	р
Pre-PMC MVA (cm ²)	1.06 ± 0.23	0.92 ± 0.21	<0.0001
MR grade 2	42 (8)	17 (20)	0,01
Cormier Score 3	159 (31)	49 (59)	0,001



presence of calcification.











- Despite challenges raised by severe calcification, GIR were achieved in >3/4 patients, thus allowing to postpone surgery.
- PMC remains a valid option in <u>selected</u> patients with less favourable characteristics.



THANK YOU

29 C J OURNÉES E UROPÉENNES de la SOCIÉTÉ F RANÇAISE de CARDIOLOGIE 29 C E UROPEAN D'AYS of the F RENCH SOCIETY of CARDIOLOGY